Literature DB >> 33256824

How I approach membrane lung dysfunction in patients receiving ECMO.

Bishoy Zakhary1, Leen Vercaemst2, Phillip Mason3, Marta V Antonini4,5, Roberto Lorusso6, Daniel Brodie7,8.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33256824      PMCID: PMC7704102          DOI: 10.1186/s13054-020-03388-2

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.

Introduction

With improvements in circuit technology and expanding supportive evidence, extracorporeal membrane oxygenation (ECMO) use has grown rapidly over the past decade [1]. Advances in pump and membrane lung (ML) design have led to simpler and more efficient circuits. Circuit-related complications, however, remain frequent and associated with considerable morbidity [2].

Mechanisms of membrane lung dysfunction

The ML is responsible for oxygen uptake and carbon dioxide removal. The non-biologic surface of the ML activates inflammatory and coagulation pathways with thrombus formation, fibrinolysis, and leukocyte activation [3-5] leading to ML dysfunction. Activation of coagulation and fibrinolysis can precipitate systemic coagulopathy or hemolysis, while clot deposition can obstruct blood flow [6, 7]. Additionally, moisture buildup in the gas phase and protein and cellular debris accumulation in the blood phase may contribute to shunt and dead-space physiology, respectively, impairing gas exchange [8, 9]. These three categories—hematologic abnormalities, mechanical obstruction, and inadequate gas exchange—prompt the majority of ML exchanges.

Membrane lung monitoring

Hematologic profile

Monitoring of hematologic variables, including coagulation and hemolysis labs, can help identify the development of an ECMO coagulopathy or hemolysis.

Pressure monitoring

The pressure drop across the ML (ΔP) is measured as (Additional file 1: Supplemental Figure):where PPre = pre-ML pressure, PPost = post-ML pressure. As clot forms in the ML, increases in resistance (RML) are reflected as increases in ΔP. To correct for changes in blood flow rate (BFR), monitoring of ΔP normalized for BF rate (ΔP/BFR) more directly reflects RML.

Membrane lung gas transfer

Applying the Fick principle across the ML, oxygen (O2) transfer may be calculated as: where V′O2 = O2 transfer across the ML (mL/min), BFR = blood flow rate (L/min), CO2 = O2 content of (pre-/post-ML) blood (mL/L) forwhere Hb = hemoglobin (g/dL), SO2 = O2 saturation of (pre-/post-ML) blood, PO2 = O2 partial pressure of (pre-/post-ML) blood (mmHg). Measurement of V′O2 provides an objective measure of oxygen transfer and can confirm ML dysfunction, when clinically indicated.

Membrane lung dysfunction

Prompt recognition of ML dysfunction is vital for safety, allowing for elective replacement in a controlled manner. On the other hand, replacement of an adequately functioning device—requiring temporary cessation of ECMO support—places the patient at unnecessary risk while consuming a limited and expensive resource. Based on the pathophysiology of the ML, replacement may be required for one of three reasons: if there is (A) an associated hematologic abnormality, (B) an increasing obstruction to blood flow, or (C) inadequate gas exchange (Fig. 1).
Fig. 1

Algorithmic approach to membrane lung monitoring for membrane lung dysfunction. Cut-off values for consideration of ML exchange are suggested values based on author experience and should be considered in the context of the patient and dependence on ECMO support. Please refer to text for details. ML, membrane lung; Plt, platelet count; INR, international normalized ratio; aPTT, activated partial thromboplastin time; fHb, free hemoglobin; LDH, lactate dehydrogenase; ΔP, Pressure drop across the ML; PPre, pre-ML pressure; PPost, post-ML pressure; RML, resistance within the ML; BFR, blood flow rate; V′O2, membrane lung oxygen uptake; CPreO2, O2 content of pre-ML blood; CPostO2, O2 content of post-ML blood; PPreO2, partial pressure of pre-ML O2; PPostO2, partial pressure of post-ML O2; PPreCO2, partial pressure of pre-ML CO2; PPostCO2, partial pressure of post-ML CO2. Flowchart is designed with adult ECMO patients in mind and may not be applicable to pediatric or neonatal patients. *Extent and frequency of coagulation and hemolysis lab monitoring is not well-established and will vary by center. Not all labs are required to diagnose coagulopathy or hemolysis. **When a ML fails, we recommend considering switching the entire circuit, rather than just the ML, if: (a) the ML and pump head are fused; (b) the ML dysfunction occurs in the setting of circuit-related coagulopathy; or (c) the ML dysfunction occurs in the setting of an older circuit (i.e., longer than 2 weeks). While the first is due to technical limitation, the latter aim to reduce the risk of ongoing or new circuit-related coagulopathy in circuits at risk for this phenomenon

Algorithmic approach to membrane lung monitoring for membrane lung dysfunction. Cut-off values for consideration of ML exchange are suggested values based on author experience and should be considered in the context of the patient and dependence on ECMO support. Please refer to text for details. ML, membrane lung; Plt, platelet count; INR, international normalized ratio; aPTT, activated partial thromboplastin time; fHb, free hemoglobin; LDH, lactate dehydrogenase; ΔP, Pressure drop across the ML; PPre, pre-ML pressure; PPost, post-ML pressure; RML, resistance within the ML; BFR, blood flow rate; V′O2, membrane lung oxygen uptake; CPreO2, O2 content of pre-ML blood; CPostO2, O2 content of post-ML blood; PPreO2, partial pressure of pre-ML O2; PPostO2, partial pressure of post-ML O2; PPreCO2, partial pressure of pre-ML CO2; PPostCO2, partial pressure of post-ML CO2. Flowchart is designed with adult ECMO patients in mind and may not be applicable to pediatric or neonatal patients. *Extent and frequency of coagulation and hemolysis lab monitoring is not well-established and will vary by center. Not all labs are required to diagnose coagulopathy or hemolysis. **When a ML fails, we recommend considering switching the entire circuit, rather than just the ML, if: (a) the ML and pump head are fused; (b) the ML dysfunction occurs in the setting of circuit-related coagulopathy; or (c) the ML dysfunction occurs in the setting of an older circuit (i.e., longer than 2 weeks). While the first is due to technical limitation, the latter aim to reduce the risk of ongoing or new circuit-related coagulopathy in circuits at risk for this phenomenon

Hematologic abnormalities

The presence of an ECMO coagulopathy, typified by elevated clotting times, hypofibrinogenemia, thrombocytopenia, and elevated D-dimer without alternate explanation raises concern for circuit-related coagulopathy (CRC). Alternatively, evidence of hemolysis with elevated plasma-free hemoglobin, without alternate explanation, is concerning for circuit-related hemolysis. In both cases, the diagnosis is presumptive and only confirmed when values normalize after circuit exchange [6].

Obstruction to blood flow

Increasing ΔP/BFR suggests increasing ML clot burden. As different MLs have different RML, no cut-off values of ΔP define ML dysfunction and the trend should be carefully considered. A rapidly increasing ΔP, even if not associated with reduced gas exchange efficiency, is often a harbinger of impending ML failure and should prompt consideration of ML exchange. When ML pressures are not measured, an increasing pump speed requirement to maintain a stable BFR can serve as a surrogate for increasing ΔP, with the caveat that pump preload and afterload also affect this relationship.

Inadequate oxygen uptake

Worsening oxygenation during ECMO should prompt quantification of oxygen transfer. When the ML is no longer able to meet patient oxygen demand, ML exchange is indicated. There are three important considerations in making this decision. First, it is necessary that measured V′O2 is truly a maximal value. If circuit BFR is low, for example, the blood will be fully saturated early in the ML path and reserve will exist for additional oxygen transfer as BFR is increased. Similarly, if CPreO2 is artificially elevated, due to high recirculation fraction or impaired tissue extraction, or if the fraction of delivered oxygen in the sweep gas (FDO2) is below 100%, the gradient driving oxygen transfer is reduced, and measured V′O2 may not represent maximal capacity. As such, BFR should be sufficiently high that further increases do not increase arterial saturation, recirculation fraction should be minimized, and ML FDO2 set to 100% to ensure an accurate assessment of maximal V′O2. Second, though PPost-MLO2 less than 200 mmHg can suggest a failing ML [6], it is vital to calculate V′O2 for confirmation. In the setting of low CPreO2 or high circuit BFR, blood exiting the ML may not be fully saturated, with low PPostO2, despite normal V′O2. In this case, if the ML is exchanged, the patient is placed at risk without subsequent improvement in oxygen delivery. Finally, no absolute values diagnose inadequate oxygen transfer and clinical context is important. In general, however, in a patient with hypoxemia and a ML with maximal V′O2 < 100–150 mL/min, ML exchange is typically indicated.

Inadequate carbon dioxide clearance

ML dysfunction can also manifest as inadequate CO2 clearance. Calculation of V′CO2 is not typically performed as it varies in a nonlinear fashion with sweep gas flow rate and requires sampling ML exhaust CO2 [10]. However, persistent PPost-MLCO2 greater than 40 mmHg [6] and clearance of less than 10 mmHg PCO2 between pre- and post-ML blood gases despite sweep gas flow rates of 10 L/min or greater is suggestive of ML dysfunction and ML exchange should be considered.

Sudden membrane lung failure

While serial monitoring of the ML may identify markers of dysfunction and allow for elective exchange, acute ML failure is a potentially life-threatening event with unique considerations. Mechanisms to ensure optimal management are provided in the Additional file 2.

Conclusion

The decision to exchange a ML is complex and without clear guidelines. In this manuscript, we outline a physiologic approach to troubleshooting this common yet high risk event. Additional file 1. Membrane lung monitoring of pressure drop and oxygen transfer. Additional file 2. Sudden Membrane Lung Failure.
  8 in total

1.  Analysis of thrombotic deposits in extracorporeal membrane oxygenators by multidetector computed tomography.

Authors:  Christian Dornia; Alois Philipp; Stefan Bauer; Matthias Lubnow; Thomas Müller; Karla Lehle; Christof Schmid; René Müller-Wille; Philipp Wiggermann; Christian Stroszczynski; Andreas G Schreyer
Journal:  ASAIO J       Date:  2014 Nov-Dec       Impact factor: 2.872

2.  Thrombosis in centrifugal pumps: location and composition in clinical and in vitro circuits.

Authors:  Susan M Hastings; Shriprasad R Deshpande; Scott Wagoner; Kevin Maher; David N Ku
Journal:  Int J Artif Organs       Date:  2016-06-02       Impact factor: 1.595

3.  Extracorporeal membrane oxygenation and V/Q ratios: an ex vivo analysis of CO2 clearance within the Maquet Quadrox-iD oxygenator.

Authors:  Bishoy Zakhary; Jayne Sheldrake; Vincent Pellegrino
Journal:  Perfusion       Date:  2020-05       Impact factor: 1.972

Review 4.  Oxygenator performance and artificial-native lung interaction.

Authors:  Francesco Epis; Mirko Belliato
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

5.  Efficiency in extracorporeal membrane oxygenation-cellular deposits on polymethylpentene membranes increase resistance to blood flow and reduce gas exchange capacity.

Authors:  Karla Lehle; Alois Philipp; Otto Gleich; Andreas Holzamer; Thomas Müller; Thomas Bein; Christof Schmid
Journal:  ASAIO J       Date:  2008 Nov-Dec       Impact factor: 2.872

Review 6.  Extracorporeal Life Support for Adults With Respiratory Failure and Related Indications: A Review.

Authors:  Daniel Brodie; Arthur S Slutsky; Alain Combes
Journal:  JAMA       Date:  2019-08-13       Impact factor: 56.272

7.  Technical complications during veno-venous extracorporeal membrane oxygenation and their relevance predicting a system-exchange--retrospective analysis of 265 cases.

Authors:  Matthias Lubnow; Alois Philipp; Maik Foltan; Tone Bull Enger; Dirk Lunz; Thomas Bein; Assad Haneya; Christof Schmid; Günter Riegger; Thomas Müller; Karla Lehle
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

Review 8.  Current Understanding of How Extracorporeal Membrane Oxygenators Activate Haemostasis and Other Blood Components.

Authors:  Andrew J Doyle; Beverley J Hunt
Journal:  Front Med (Lausanne)       Date:  2018-12-12
  8 in total
  3 in total

Review 1.  Thrombosis and coagulopathy in COVID-19 patients rceiving ECMO: A narrative review of current literature.

Authors:  Hakeem Yusuff; Vasileios Zochios; Daniel Brodie
Journal:  J Cardiothorac Vasc Anesth       Date:  2022-03-31       Impact factor: 2.894

2.  Heparin-free after 3000 IU heparin loaded in veno-venous ECMO supported acute respiratory failure patients with hemorrhage risk: a novel anti-coagulation strategy.

Authors:  Yang-Chao Zhao; Xi Zhao; Guo-Wei Fu; Ming-Jun Huang; Xing-Xing Li; Qian-Qian Sun; Ya-Bai Kan; Jun Li; Shi-Lei Wang; Wen-Tao Ma; Qin-Fu Xu; Qi-Long Liu; Hong-Bin Li
Journal:  Thromb J       Date:  2022-06-27

3.  Dynamic oxygenator blood volume during prolonged extracorporeal life support.

Authors:  Rik H J Hendrix; Eva R Kurniawati; Sanne F C Schins; Jos G Maessen; Patrick W Weerwind
Journal:  PLoS One       Date:  2022-02-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.